INDIANAPOLIS, Jan. 09, 2026 (GLOBE NEWSWIRE) — Hurco Companies, Inc. (Nasdaq: HURC) today reported results for the fourth fiscal quarter and fiscal year ended October 31, 2025. Hurco recorded a net loss of $3,041,000, or $0.47 per diluted share, for the fourth quarter of fiscal year 2025, compared to a net loss of $1,442,000, or $0.23 per diluted share, for the corresponding period in fiscal year 2024. Hurco recorded a net loss of $15,117,000, or $2.34 per diluted share, for fiscal year 2025, compared to a net loss of $16,608,000, or $2.56 per diluted share, for fiscal year 2024. The recorded net losses for fiscal years 2025 and 2024, included non-cash tax valuation allowances of $4,778,000 and $8,590,000, respectively, recorded in provision for income taxes. Sales and service fees for the fourth quarter of fiscal year 2025 were...

Estimated YUTREPIA™ net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year 2025 Received more than 2,800 unique patient prescriptions since launch in June 2025 Generated more than $30 million of positive cash flow during the fourth quarter 2025MORRISVILLE, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced preliminary, unaudited full-year 2025 net product sales of YUTREPIA™ (treprostinil) inhalation powder, as well as updates on the commercial launch and the clinical pipeline. These updates will be discussed during Liquidia’s participation in the 44th Annual J.P. Morgan Healthcare...

Sanuwave is pleased to announce preliminary revenues of $13.3 million to $13.4 million for the fourth quarter ended December 31, 2025. This represents the highest quarterly revenues in Company history. Q4 2025 revenue increased between 29% and 30% compared to Q4 2024. Full Year 2025 revenue increased to $44.3-$44.4 million up 36% vs Full Year 2024. 2025 annual revenues were an all-time record for the Company. EDEN PRAIRIE, Minn., Jan. 09, 2026 (GLOBE NEWSWIRE) — Sanuwave Health, Inc. (the “Company” or “Sanuwave”) (NASDAQ: SNWV), a leading provider of FDA-approved directed energy systems used in advanced wound care, today announced that revenues for the fourth quarter of 2025 are expected to be in the range of $13.3 to $13.4 million, an increase of 29% to 30% over Q4 2024. This number is within the range of guidance...

Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Tecan reports return to sales growth and strong order entry in the second half of 2025Group sales of CHF 882.5 million, down 1.6% in local currencies for the year, with second-half sales growth of 0.4% Order entry increased by 3.8% in local currencies for the full year and by 8.6% in the second halfMännedorf, Switzerland, January 9, 2026 – In a trading statement, the Tecan Group (SIX Swiss Exchange: TECN) today published unaudited preliminary results for fiscal year 2025, reporting moderate sales growth and strong order entry in local currencies in the second half. For the full year, sales in local currencies were in line with the sales outlook last confirmed on October 13, 2025. Group sales for 2025 decreased by 1.6% in local currencies and 5.5%...

TORONTO, Jan. 08, 2026 (GLOBE NEWSWIRE) — Nexus Industrial REIT (“Nexus” or the “REIT”) (TSX: NXR.UN) announced today that it intends to release its financial results for the fourth quarter and year ended December 31, 2025, before the opening of the TSX on Friday, March 6, 2026. Management of the REIT will host a conference call at 10:00 AM Eastern Standard Time on Friday March 6, 2026, to review the financial results and operations. To participate in the conference call, please dial 1-647-846-8414 or 1-833-752-3601 (toll free in Canada and the US) at least five minutes prior to the start time and ask to join the Nexus Industrial REIT conference call. A recording of the conference call will be available until April 6, 2026. To access the recording, please dial 1-412-317-0088 or 1-855-669-9658 (toll free in Canada and...

DENVER, Jan. 08, 2026 (GLOBE NEWSWIRE) — National Bank Holdings Corporation (NYSE: NBHC) expects to report its fourth quarter and full year 2025 financial results after the markets close on Tuesday, January 27, 2026. Management will host a conference call to review the results at 11:00 a.m. Eastern Time on Wednesday, January 28, 2026. The call may also include discussion of company developments, forward-looking statements and other material information about business and financial matters. Interested parties may listen to this call by dialing (800) 330-6710 using the participant passcode of 6983606 and asking for the NBHC Q4 2025 Earnings Call. A recording of the call will be available approximately four hours after the call’s completion on the company’s website at www.nationalbankholdings.com by visiting the investor relations...

International Medical Cannabis Revenue Increases 36%; Canadian Adult-Use Cannabis Revenue Grows 6% Tilray Pharma Achieves Record Quarterly Revenue U.S. Federal Cannabis Rescheduling Expected to Unlock New Market Opportunity for Tilray Medical Expansion into the U.S. Strong Financial Position with $292 Million in Cash and Marketable Securities1 and ~$30 Million Net Cash NEW YORK and LONDON and LEAMINGTON, Ontario, Jan. 08, 2026 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray”, “our”, “we” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the cannabis, beverage, and wellness industries, today reported financial results for its second fiscal quarter ended November 30, 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise...

SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) — Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2026 on Thursday, January 29, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.Earnings webcast details:• Location: https://investor.resmed.com• Date: Thursday, January 29, 2026• Time: 1:30 p.m. PST / 4:30 p.m. EST• International: London, Thursday, January 29, 2026, 9:30 p.m. GMT    Sydney, Friday, January 30, 2026, 8:30 a.m. AEDTPlease note, Resmed does not use outside phone lines to access the earnings call, the call is accessible via the above webcast link only. A...

— Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years– BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) — Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported preliminary, unaudited total revenue of $726.4 million for the year ended December 31, 2025, compared with $701.0 million for the year ended December 31, 2024. The company also repurchased 2.0 million shares of its common stock during the fourth quarter. “We closed 2025 having achieved another year of solid execution and meaningful progress advancing our 5×30 strategic priorities, leaving us well-positioned for sustainable, long-term success,” said Frank D. Lee,...

LOS ANGELES, Jan. 08, 2026 (GLOBE NEWSWIRE) — AXIL Brands, Inc. (“AXIL,” “we,” “us,” “our,” or the “Company”) (NYSE American: AXIL), an emerging global consumer products company for AXIL® hearing protection and enhancement products and Reviv3® hair and skin care products, today announced financial and operational results for the second quarter ended November 30, 2025 (2Q26). Financial Highlights (Quarter Ended November 30, 2025)Net sales increased to $8.1 million, compared to $7.7 million in the prior year period, an increase of 5.2% Gross profit of $5.5 million, or 68.1% of sales, compared to $5.5 million, or 71.1% in the prior year period Operating expenses declined to $4.6 million, or 57.0% of net sales compared to $4.8 million, or 62.4% of net sales in the prior year period Net income increased to $704,833, compared to $633,706...